Clinical trial
Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged…
NCT00150618 · Shire, Industry · Completed
Key facts
| NCT number | NCT00150618 |
|---|---|
| Title | Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17 |
| Official title | A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention Deficit Hyperactivity Disorder (ADHD) |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Disorder With Hyperactivity |
| Intervention type | Drug |
| Interventions | SPD503 (1 mg), SPD503 (2 mg), SPD503 (3 mg), SPD503 (4 mg), Placebo |
| Enrollment | 324 |
| Start date | Mar 30, 2004 |
| Primary completion | Oct 7, 2004 |
| Completion | Oct 7, 2004 |
| First posted | Sep 8, 2005 |
| Last update posted | Jun 10, 2021 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: